Trial Profile
Phase II study for efficacy and safety of pembrolizumab for chemotherapy unfit previously untreated patients highly expressing PD-L1 positive advanced non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2019
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Mar 2017 New trial record